KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Retained Earnings (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Retained Earnings for 8 consecutive years, with -$1.7 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 6.7% year-over-year to -$1.7 billion, compared with a TTM value of -$1.7 billion through Sep 2025, down 6.7%, and an annual FY2024 reading of -$1.6 billion, down 3.34% over the prior year.
  • Retained Earnings was -$1.7 billion for Q3 2025 at Esperion Therapeutics, down from -$1.7 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$2000.0 in Q4 2022 and bottomed at -$1.7 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$1.2 billion, with a median of -$1.4 billion recorded in 2023.
  • The sharpest move saw Retained Earnings skyrocketed 93.55% in 2022, then plummeted 77464100.0% in 2023.
  • Year by year, Retained Earnings stood at -$31000.0 in 2021, then skyrocketed by 93.55% to -$2000.0 in 2022, then tumbled by 77464100.0% to -$1.5 billion in 2023, then fell by 3.34% to -$1.6 billion in 2024, then dropped by 5.28% to -$1.7 billion in 2025.
  • Business Quant data shows Retained Earnings for ESPR at -$1.7 billion in Q3 2025, -$1.7 billion in Q2 2025, and -$1.6 billion in Q1 2025.